EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Photodynamic diagnosis‐assisted transurethral resection of bladder tumor for high‐risk non‐muscle invasive bladder cancer improves intravesical recurrence‐free survival (BRIGHT study)

Taketo Kawai iD, Hideyasu Matsuyama, Keita Kobayashi iD, Atsushi Ikeda, Makito Miyake iD, Koshiro Nishimoto iD, Yuto Matsushita iD, Hiroyuki Nishiyama, Kiyohide Fujimoto iD, Masafumi Oyama, Hideaki Miyake, Haruhito Azuma und 8 weitere

International Journal of Urology · 2024-08 · 31 (8) · 906-912

DOI: 10.1111/iju.15483 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Urology, online erschienen am 02.05.2024. Verfasst von Taketo Kawai und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Teikyo University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Aminolevulinic Acid, Neoplasm Recurrence, Local, Non-Muscle Invasive Bladder Neoplasms, Photosensitizing Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chugai Pharmaceutical Co., Ltd., SBI Pharmaceuticals Co., Ltd., Chugai Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

In a primary analysis of data from the BRIGHT study (UMIN000035712), photodynamic diagnosis‐assisted transurethral resection of bladder tumor (PDD‐TURBT) using oral 5‐aminolevulinic acid hydrochloride reduced residual tumors in high‐risk non‐muscle invasive bladder cancer (NMIBC). We aimed to evaluate the effectiveness of PDD‐TURBT for intravesical recurrence after a second transurethral resection for high‐risk NMIBC.

Methods

High‐risk NMIBC patients initially treated with PDD‐TURBT (PDD group) were prospectively registered between 2018 and 2020. High‐risk patients with NMIBC who were initially treated with white‐light TURBT (WL group) were retrospectively registered. Intravesical recurrence‐free survival after the second transurethral resection was compared between the PDD and WL groups using propensity score matching analysis.

Results

In total, 177 patients were enrolled in the PDD group, and 306 patients were registered in the WL group. After propensity score matching (146 cases in each group), intravesical recurrence within 1 year was significantly less frequent in the PDD group than in the WL group ( p = 0.004; hazard ratio [HR] 0.44, 95% confidence interval [CI]: 0.25–0.77). In subgroup analysis, PDD‐TURBT showed a particularly high efficacy in reducing intravesical recurrence within 1 year, especially in cases of tumors measuring less than 3 cm ( p = 0.003; HR 0.31, 95% CI: 0.14–0.67), absence of residual tumor at second transurethral resection ( p = 0.020; HR 0.37, 95% CI: 0.16–0.86), and no postoperative intravesical Bacillus Calmette‐Guérin therapy ( p < 0.001; HR 0.27, 95% CI: 0.13–0.58).

Conclusions

PDD‐TURBT may reduce short‐term intravesical recurrence in patients with high‐risk NMIBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aminolevulinic AcidNeoplasm Recurrence, LocalNon-Muscle Invasive Bladder NeoplasmsPhotosensitizing AgentsAgedFemaleHumansMaleCystectomyDisease-Free SurvivalNeoplasm InvasivenessNeoplasm, ResidualPropensity ScoreProspective StudiesRetrospective StudiesTransurethral Resection of Bladder

Stichwörter der Autor:innen

5‐aminolevulinic acidhigh‐risk non‐muscle invasive bladder cancerintravesical recurrencephotodynamic diagnosispropensity score matching

Substanzen

Aminolevulinic AcidPhotosensitizing Agents

Autor:innen und Institutionen

  • Department of Urology, Teikyo University School of Medicine, Tokyo, Japan.
  • Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Japan.
  • Department of Urology, JA Yamaguchi Kouseiren Nagato General Hospital, Nagato, Japan.
  • Department of Urology, Institute of Medicine, University of Tsukuba, Tsukuba, Japan.
  • Department of Urology, Nara Medical University, Kashihara, Japan.

ORCID-Profile: Taketo Kawai, Keita Kobayashi, Makito Miyake, Koshiro Nishimoto, Yuto Matsushita, Kiyohide Fujimoto, Takahiko Mitsui, Atsushi Mizokami, Takashige Abe

Förderung

  • Chugai Pharmaceutical Co., Ltd.
  • SBI Pharmaceuticals Co., Ltd.
  • Chugai Pharmaceutical

Zitieren

APA

Kawai, T., Matsuyama, H., Kobayashi, K., Ikeda, A., Miyake, M., Nishimoto, K., Matsushita, Y., Nishiyama, H., Fujimoto, K., Oyama, M., Miyake, H., Azuma, H., Inoue, K., Mitsui, T., Kawakita, M., Oyama, C., Mizokami, A., Abe, T., Kuroiwa, H., & Kume, H. (2024). Photodynamic diagnosis‐assisted transurethral resection of bladder tumor for high‐risk non‐muscle invasive bladder cancer improves intravesical recurrence‐free survival (BRIGHT study). International Journal of Urology, 31(8), 906-912. https://doi.org/10.1111/iju.15483

Vancouver

Kawai T, Matsuyama H, Kobayashi K, Ikeda A, Miyake M, Nishimoto K, et al. Photodynamic diagnosis‐assisted transurethral resection of bladder tumor for high‐risk non‐muscle invasive bladder cancer improves intravesical recurrence‐free survival (BRIGHT study). International Journal of Urology. 2024;31(8):906-912. doi:10.1111/iju.15483

BibTeX
@article{Kawai2024,
  author = {Kawai, Taketo and Matsuyama, Hideyasu and Kobayashi, Keita and Ikeda, Atsushi and Miyake, Makito and Nishimoto, Koshiro and Matsushita, Yuto and Nishiyama, Hiroyuki and Fujimoto, Kiyohide and Oyama, Masafumi and Miyake, Hideaki and Azuma, Haruhito and Inoue, Keiji and Mitsui, Takahiko and Kawakita, Mutsushi and Oyama, Chikara and Mizokami, Atsushi and Abe, Takashige and Kuroiwa, Hajime and Kume, Haruki},
  title = {Photodynamic diagnosis‐assisted transurethral resection of bladder tumor for high‐risk non‐muscle invasive bladder cancer improves intravesical recurrence‐free survival (BRIGHT study)},
  journal = {International Journal of Urology},
  year = {2024},
  volume = {31},
  number = {8},
  pages = {906--912},
  doi = {10.1111/iju.15483}
}
Kostenlos starten →